Truist downgraded Penumbra (PEN) to Hold from Buy with a price target of $374, up from $370. The firm cites the recent announcement of its acquisition by Boston Scientific for the downgrade. The deal is highly likely to close without issue, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN: